Ionis EVP exercises options, sells 60,846 shares
Ionis Pharmaceuticals EVP and Chief Development Officer Holly B. Kordasiewicz reported an exercise-and-sell transaction in Ionis common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Ionis Pharmaceuticals EVP and Chief Development Officer Holly B. Kordasiewicz reported an exercise-and-sell transaction in Ionis common stock. On June 12, 2026, she sold a total of 60,846 shares in open-market sales, including 19,842 shares at a weighted average price of $74.0503 per share and 41,004 shares at a weighted average price of $73.0934 per share.
The sales were made under a pre-arranged Rule 10b5-1 Trading Plan adopted on March 13, 2026, meaning the trades were scheduled in advance. On the same date, she exercised non-qualified stock options covering a total of 60,846 shares of common stock at exercise prices of $32.60, $56.78, and $60.89 per share, converting derivative awards into shares that were then largely sold for liquidity.
Insider Trade Summary 10b5-1
Exercise and Sale: 60,846 shares ($1.18M approx. pre-tax spread)
Exercise and Sale
10 txns
Insider
Kordasiewicz Holly B.
Role
EVP, Chief Development Officer
Sold
60,846 shs ($4.47M)
Approx. gross sale proceeds
$4.47M
Approx. exercise cost
$3.28M
Approx. pre-tax spread
$1.18M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 12,000 | $0.00 | $0.00 |
| Exercise | Non-Qualified Stock Option (right to buy) | 19,895 | $0.00 | $0.00 |
| Exercise | Non-Qualified Stock Option (right to buy) | 7,951 | $0.00 | $0.00 |
| Exercise | Non-Qualified Stock Option (right to buy) | 21,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 7,951 | $60.89 | $484K |
| Exercise | Common Stock | 21,000 | $60.89 | $1.28M |
| Exercise | Common Stock | 12,000 | $32.60 | $391K |
| Exercise | Common Stock | 19,895 | $56.78 | $1.13M |
| Sale | Common Stock | 41,004 | $73.0934 | $3.00M |
| Sale | Common Stock | 19,842 | $74.0503 | $1.47M |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 0 contracts (Direct);
Common Stock — 22,458 shares (Direct)
Footnotes (3)
- F1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2026
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.68 to $73.67 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.735 to $74.28 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
Key Figures
Total shares sold: 60,846 shares
Sale block 1: 41,004 shares at $73.0934/share
Sale block 2: 19,842 shares at $74.0503/share
+5 more
8 metrics
Total shares sold
60,846 shares
Common stock sold in open-market transactions on June 12, 2026
Sale block 1
41,004 shares at $73.0934/share
Weighted average price for one sale block of common stock
Sale block 2
19,842 shares at $74.0503/share
Weighted average price for second sale block of common stock
Option exercises
60,846 shares
Common shares acquired via option exercises on June 12, 2026
Exercise price 1
$32.60/share
Exercise price of one tranche of non-qualified stock options
Exercise price 2
$56.78/share
Exercise price of second tranche of non-qualified stock options
Exercise price 3
$60.89/share
Exercise price of additional non-qualified stock options
Net buy/sell shares
60,846 shares net sold
Net share change across all reported buy/sell transactions
Key Terms
Rule 10b5-1 Trading Plan, Non-Qualified Stock Option (right to buy), weighted average price
3 terms
Rule 10b5-1 Trading Plan financial
"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2026"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Non-Qualified Stock Option (right to buy) financial
"Non-Qualified Stock Option (right to buy) with an underlying security of Common Stock"
weighted average price financial
"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Ionis Pharmaceuticals (IONS) report for Holly B. Kordasiewicz?
Holly B. Kordasiewicz reported an exercise-and-sell transaction in Ionis common stock. She exercised options for 60,846 shares, then sold 60,846 shares in open-market trades on June 12, 2026, as disclosed in the Form 4.
Were Holly B. Kordasiewicz’s Ionis (IONS) stock sales made under a Rule 10b5-1 plan?
Yes. The Form 4 states that the shares sold were pursuant to a Rule 10b5-1 Trading Plan adopted by Holly B. Kordasiewicz on March 13, 2026, indicating the sales were pre-scheduled rather than discretionary market-timing decisions.
What stock options did Holly B. Kordasiewicz exercise in Ionis Pharmaceuticals (IONS)?
She exercised non-qualified stock options for 60,846 shares of Ionis common stock. The exercised options carried exercise prices of $32.60, $56.78, and $60.89 per share, converting derivative awards into common shares on June 12, 2026.
What price ranges applied to the Ionis (IONS) insider stock sales reported by Holly B. Kordasiewicz?
The Form 4 notes that weighted average prices reflect multiple trades. One sale block occurred between $72.68 and $73.67 per share, and another between $73.735 and $74.28 per share, with full trade-by-trade details available upon request.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates